The Inhibitory Effects of Cuminaldehyde on Amyloid Fibrillation and Cytotoxicity of Alpha-synuclein

Authors
D. Morshedi
F. Aliakbari
National Institute of Genetic Engineering and Biotechnology, Tehran, Iran
Abstract
Objective: Alpha-synuclein is a major component of protein plaques in synucleinopathies, particularly Parkinson’s disease. The purpose of this study is to assess the inhibitory effects of cuminaldehyde on the fibrillation of alpha-synuclein.
Methods: Alpha-synuclein was expressed in Escherichia coli and subsequently purified. For the process of fibrillation, purified protein was incubated at 37◦C and pH 7.2. Fibrillation was analyzed by the standard fibril methods. The effects of different concentrations of cuminaldehyde (20-500 μM) on alpha-synuclein fibrillation were studied by assessment of the cytotoxic effects of samples on the neuroblastoma cell line, SK-N-MC. To study the protein aggregation forms that were generated in the presence of cuminaldehyde, SDS resistance and induced fibrillation (seeding) methods were employed. For studying its specificity on alpha-synuclein, the effect of cuminaldehyde on lysozyme fibrillation was also examined.
Results: We showed, for the first time, that cuminaldehyde inhibited fibrillation by more than 80%. The highest inhibition was observed at the ratio of 5-15 moles of drug to protein. The viability of the treated cells with inhibited proteins was more than 90%, whereas non-inhibited samples caused a decrease in viability by 50%. Inhibited samples were not resistant to SDS and they were unable to induce fibrillation. Cuminaldehyde did not inhibit lysozyme fibrillation.
Conclusion: Cuminaldehyde inhibited fibrillation of alpha-synuclein which was accompanied by small amorphous aggregated particles of alpha synuclein. The inhibited protein samples did not induce aggregation. Thus, cuminaldehyde can be considered as a candidate to inhibit the formation of alpha-synuclein plaques.

Keywords

 
 
[1]   Luheshi LM, Crowther DC, Dobson CM. Protein misfolding and disease: from the test tube to the organism. Curr Opin Chem Biol 2008; 12(1): 25-31.
[2]   Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol 2007; 8(2): 101-12.
[3]   Ladiwala AR, Lin JC, Bale SS, Marcelino-Cruz AM, Bhattacharya M, Dordick JS, Tessier PM. Resveratrol selectively remodels soluble oligomers and fibrils of amyloid Abeta into off-pathway conformers. J Biol Chem 2010; 285(31): 24228-37.
[4]   Suk JE, Lokappa SB, Ulmer TS. The clustering and spatial arrangement of beta-sheet sequence, but not order, govern alpha-synuclein fibrillogenesis. Biochemistry 2010; 49(7): 1533-40.
[5]   Chung JY, Lee SJ, Lee SH, Jung YS, Ha NC, Seol W, Park BJ. Direct interaction of α-synuclein and AKT regulates IGF-1 signaling: implication of Parkinson disease. Neurosignals 2011; 19(2):86-96.
[6]   Puschmann A, Ross OA, Vilariño-Güell C, Lincoln SJ, Kachergus JM, Cobb SA, Lindquist SG, Nielsen JE, Wszolek ZK, Farrer M, Widner H, van Westen D, Hägerström D, Markopoulou K, Chase BA, Nilsson K, Reimer J, Nilsson C. A Swedish family with de novo alpha-synuclein A53T mutation: evidence for early cortical dysfunction. Parkinsonism Relat Disord 2009; 15(9): 627-32.
[7]   Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos ES, Chandrasekharappa S, Athanassiadou A, Papapetropoulos T, Johnson WG, Lazzarini AM, Duvoisin RC, Di Iorio G, Golbe LI, Nussbaum RL. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997; 276(5321): 2045-7.
[8]   Waxman EA, Giasson BI. Molecular mechanisms of alpha-synuclein neuro-degeneration. Biochim Biophys Acta 2009; 1792(7): 616-24.
[9]   Del Mar C, Greenbaum EA, Mayne L, Englander SW, Woods VL Jr. Structure and properties of alpha-synuclein and other amyloids determined at the amino acid level. Proc Natl Acad Sci USA 2005; 102(43): 15477-82.
[10] Frimpong AK, Abzalimov RR, Uversky VN, Kaltashov IA. Characterization of intrinsically disordered proteins with electrospray ionization mass spectrometry: conformational heterogeneity of alpha-synuclein. Proteins 2009; 78(3): 714-22.
[11] Georgieva ER, Ramlall TF, Borbat PP, Freed JH, Eliezer D. Membrane-bound alpha-synuclein forms an extended helix: long-distance pulsed ESR measurements using vesicles, bicelles, and rodlike micelles. J Am Chem Soc 2008; 130(39): 12856-7.
[12] Lokappa SB, Ulmer TS. Alpha-synuclein populates both elongated and broken helix states on small unilamellar vesicles. J Biol Chem 2011; 286(24): 21450-7.
[13] Waxman EA, Mazzulli JR, Giasson BI. Characterization of hydrophobic residue requirements for alpha-synuclein fibrillization. Biochemistry 2009; 48(40): 9427-36.
[14] Fernández CO, Hoyer W, Zweckstetter M, Jares-Erijman EA, Subramaniam V, Griesinger C, Jovin TM. NMR of alpha-synuclein-polyamine complexes elucidates the mechanism and kinetics of induced aggregation. EMBO J 2004; 23(10): 2039-46.
[15] Lee HJ, Kang SJ, Lee K, Im H. Human α-synuclein modulates vesicle trafficking through its interaction with prenylated Rab acceptor protein 1. Biochem Biophys Res Commun 2011; 412(4): 526-31.
[16] Yamaguchi Y, Masuda M, Sasakawa H, Nonaka T, Hanashima S, Hisanaga S, Kato K, Hasegawa M. Characterization of inhibitor-bound alpha-synuclein dimer: role of alpha-synuclein N-terminal region in dimerization and inhibitor binding. J Mol Biol 2009; 395(3): 445-56.
[17] Bellani S, Sousa VL, Ronzitti G, Valtorta F, Meldolesi J, Chieregatti E. The regulation of synaptic function by alpha-synuclein. Commun Integr Biol 2010; 3(2): 106-9.
[18] Braga CA, Follmer C, Palhano FL, Khattar E, Freitas MS, Romão L, Di Giovanni S, Lashuel HA, Silva JL, Foguel D. The anti-Parkinsonian drug selegiline delays the nucleation phase of α-synuclein aggregation leading to the formation of nontoxic species. J Mol Biol 2011; 405(1): 254-73.
[19] Lee EN, Cho HJ, Lee CH, Lee D, Chung KC, Paik SR. Phthalocyanine tetrasulfonates affect the amyloid formation and cytotoxicity of alpha-synuclein. Biochemistry 2004; 43(12): 3704-15.
[20]Nitoda T, Fan MD, Kubo I. Effects of cuminaldehyde on melanoma cells. Phytother Res 2008; 22(6): 809-13.
[21] O'Mahony R, Al-Khtheeri H, Weerasekera D, Fernando N, Vaira D, Holton J, Basset C. Bactericidal and anti-adhesive properties of culinary and medicinal plants against Helicobacter pylori. World J Gastroenterol 2005; 11(47): 7499-507.
[22] Pai MB, Prashant GM, Murlikrishna KS, Shivakumar KM, Chandu GN. Antifungal efficacy of Punica granatum, Acacia nilotica, Cuminum cyminum and Foeniculum vulgare on Candida albicans: an in vitro study. Indian J Dent Res 2010; 21(3): 334-6.
[23] Huang C, Ren G, Zhou H, Wang CC. A new method for purification of recombinant human alpha-synuclein in Escherichia coli. Protein Expr Purif 2005; 42(1): 173-7.
[24] Ren G, Wang X, Hao S, Hu H, Wang CC. Translocation of alpha-synuclein expressed in Escherichia coli. J Bacteriol 2007; 189(7): 2777-86.
[25] Antony T, Hoyer W, Cherny D, Heim G, Jovin TM, Subramaniam V. Cellular polyamines promote the aggregation of alpha-synuclein. J Biol Chem 2003; 278(5): 3235-40.
[26] Nilsson MR. Techniques to study amyloid fibril formation in vitro. Methods 2004; 34(1): 151-60.
[27] Malinchik SB, Inouye H, Szumowski KE, Kirschner DA. Structural analysis of Alzheimer's beta(1-40) amyloid: protofilament assembly of tubular fibrils. Biophys J 1998; 74(1): 537-45.
[28] Ban T, Hamada D, Hasegawa K, Naiki H, Goto Y. Direct observation of amyloid fibril growth monitored by thioflavin T fluorescence. J Biol Chem 2003; 278(19): 16462-5.
[29] Hansen MB, Nielsen SE, Berg K. Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J Immunol Methods 1989; 119(2):203-10.
[30] Glabe CG. Common mechanisms of amyloid oligomer pathogenesis in degenerative disease. Neurobiol Aging 2006; 27(4): 570-5.
[31] Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, Glabe CG. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 2003; 300(5618): 486-9.
[32] Falsone SF, Leitinger G, Karner A, Kungl AJ, Kosol S, Cappai R, Zangger K. The neurotransmitter serotonin interrupts α-synuclein amyloid maturation. Biochim Biophys Acta 2011; 1814(5): 553-61.
[33] Connelly L, Jang H, Arce FT, Capone R, Kotler SA, Ramachandran S, Kagan BL, Nussinov R, Lal R. Atomic force microscopy and MD simulations reveal pore-like structures of all-D-enantiomer of Alzheimer's β-amyloid peptide: relevance to the ion channel mechanism of AD pathology. J Phys Chem B 2012; 116(5): 1728-35.
[34] Mezler M, Barghorn S, Schoemaker H, Gross G, Nimmrich V. A β-amyloid oligomer directly modulates P/Q-type calcium currents in Xenopus oocytes. Br J Pharmacol 2011; 165(5): 1572-83.
[35] Quist A, Doudevski I, Lin H, Azimova R, Ng D, Frangione B, Kagan B, Ghiso J, Lal R. Amyloid ion channels: a common structural link for protein-misfolding disease. Proc Natl Acad Sci USA 2005; 102(30): 10427-32.
[36] Vabulas RM, Hartl FU. Aberrant protein interactions in amyloid disease. Cell Cycle 2011; 10(10): 1512-3.
[37] Olzscha H, Schermann SM, Woerner AC, Pinkert S, Hecht MH, Tartaglia GG, Vendruscolo M, Hayer-Hartl M, Hartl FU, Vabulas RM. Amyloid-like aggregates sequester numerous metastable proteins with essential cellular functions. Cell 2011; 144(1): 67-78.
[38] Citron M. Alzheimer's disease: strategies for disease modification. Nat Rev Drug Discov 2010; 9(5): 387-98.
[39] Middleton LE, Yaffe K. Promising strategies for the prevention of dementia. Arch Neurol 2009; 66(10): 1210-5.
[40] Nordberg A. Molecular imaging in Alzheimer's disease: new perspectives on biomarkers for early diagnosis and drug development. Alzheimers Res Ther 2010; 3(6): 34.
[41] Tian J, Ban X, Zeng H, He J, Huang B, Wang Y. Chemical composition and antifungal activity of essential oil from Cicuta virosa L. var. latisecta Celak. Int J Food Microbiol 2010; 145(2-3): 464-70.
[42] Hierro I, Valero A, Pérez P, González P, Cabo MM, Montilla MP, Navarro MC. Action of different monoterpenic compounds against Anisakis simplex s.l. L3 larvae Phytomedicine 2004; 11(1): 77-82.
[43] Morshedi D, Rezaei-Ghaleh N, Ebrahim-Habibi A, Ahmadian S, Nemat-Gorgani M. Inhibition of amyloid fibrillation of lysozyme by indole derivatives--possible mechanism of action. FEBS J 2007; 274(24): 6415-25.
[44] Lamberto GR, Binolfi A, Orcellet ML, Bertoncini CW, Zweckstetter M, Griesinger C, Fernández CO. Structural and mechanistic basis behind the inhibitory interaction of PcTS on alpha-synuclein amyloid fibril formation. Proc Natl Acad Sci USA 2009; 106(50): 21057-62.
[45] Swaminathan R, Ravi VK, Kumar S, Kumar MV, Chandra N. Lysozyme: a model protein for amyloid research. Adv Protein Chem Struct Biol 2011; 84: 63-111.
[46] Bakkali F, Averbeck S, Averbeck D, Idaomar M. Biological effects of essential oils--a review. Food Chem Toxicol 2008; 46(2): 446-75.
Pathobiology Reserach
Volume 15, Issue 1
April 2012
Pages 45-60